01
Cash & equivalents decreased 95.7%
Cash & equivalents changed -95.7% from the comparable as-filed period.
$2.9M→$124,000Comparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTAlaunos Therapeutics, Inc.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -95.7% from the comparable as-filed period.
Net income changed +9.4% from the comparable as-filed period.
Operating income changed +8.4% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
TCRT · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-352421SEC ↗4Aug 11, 2026Period Aug 6, 20260001193125-26-344682SEC ↗4Jul 27, 2026Period Jul 23, 20260001193125-26-318114SEC ↗4Jul 27, 2026Period Jul 23, 20260001193125-26-318105SEC ↗4Jul 27, 2026Period Jul 23, 20260001193125-26-318103SEC ↗4Jul 27, 2026Period Jul 23, 20260001193125-26-318100SEC ↗4Jul 2, 2026Period Jun 30, 20260001193125-26-295004SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 6, 2026Filed Aug 11, 2026 | Weis HolgerCEO | Grant Or AwardDirect | 4,363 | $2 | $8,770 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +109.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Revenue changed +0.0% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stock-based compensation changed +33.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-286914